c(RADfK)
General Information
DRACP ID DRACP05897
Peptide Name c(RADfK)
Sequence RADfK
Sequence Length 5
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Cancer targeted peptides Antiangiogenic αvβ3 Inhibitor
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
U87 | Glioblastoma | Blastoma | IC50>10 μM | MTT assay | 72 h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity HUVEC: IC50>10 μM
Target αvβ3
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Cyclic
Disulfide/Other Bond NCB: Arg1<--->Lys5
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral Mix
Physicochemical Information
Formula C19H34N8O6
Absent amino acids CEFGHILMNPQSTVWY
Common amino acids ADKR
Mass 54206
Pl 9.69
Basic residues 2
Acidic residues 1
Hydrophobic residues 1
Net charge 1
Boman Index -2738
Hydrophobicity -202
Aliphatic Index 20
Half Life
/
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 0
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Development of PEGylated doxorubicin-E-[c(RGDfK)2] conjugate for integrin-targeted cancer therapy
Doi 10.1002/pat.1731
Year 2010
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available